

Opioid, stimulants and synthetic cannabinoids users followed up to 2017

Author: Diāna Vanaga

Presenter: Linda Veisberga


Cohort of problem drug (opioid/stimulant and synthetic cannabinoid) users in Latvia (15-49 years old)

Country	Enrolment period	End of follow up	Mean age at enrolment (years)	% of males	Inclusion criteria and setting	Person-years followed up (number of participants)	Mean observation time in years	Number of deaths	CMR (per 1000 PY), 95% CI	SMR, 95% CI
Latvia	01/01/2013 to 31/12/2017	31/12/2017	29.2	80.8	Opioid/stimulant/synthetic cannabinoid recent users (used in the last 30 days)	6327.0 (n= 2315)	2.7	182	28.8 (24.9-33.2)	5.3 (4.6-6.1)

Cohort of problem drug (opioid/stimulant and synthetic cannabinoid) users in Latvia

	Opioid cohort	Stimulant cohort	Synthetic cannabinoid cohort
Number of participants	1451	893	505
Person-years	3727.2	2361.5	1722.8
Number of deaths	141	63	29
CMR (per 1000 PY)	37.8	26.7	16.8
SMR	6.1	4.9	4.3

Distribution of person-years followed up, by age-band and gender



Causes of deaths

Cause of death	ICD-10	Number (n)	Percent (%)
Infectious diseases (except HIV/AIDS)	A00-B99 (except B20-B24)	7	3,8
HIV/AIDS	B20-B24	26	14,3
Neoplasms	C00-D48	5	2,8
Diabetes mellitus	E10	1	0,6
Mental and behavioural disorders due to psychoactive substance use	F10-F19	5	2,8
Diseases of the circulatory system	I00-I99	53	29,1
Diseases of the respiratory system	J00-J99	4	2,2
Diseases of the digestive system	K00-K93	11	6,0
Unattended death	R98	3	1,6
External causes of morbidity and mortality	V01-Y98	67	36,8
Total		182	100,0

Overdose deaths regarding EMCDDA Selection B definition – 15 cases